Project Grant R21DA062805
Award Date
7/15/25
Completion Date
6/30/27
Dollars Obligated
$421K
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Bloomington, IN 47405, USA
Similar Awards
This Project Grant award of $674,709 was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) to the University of Missouri System. The grant aims to conduct a crossover study to examine the neurocircuitry and neurobiological mechanisms mediating the effects of continuous theta burst stimulation (cTBS) applied to the right inferior frontal gyrus (R.IFG) and the dorsomedial prefrontal cortex (preSMA) on inhibitory control and...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $395,566 to Flik Therapeutics, Inc. to support the development of a novel FDA-regulated pharmacotherapy and multimodal nicotine cessation program. The goal is to create a more effective smoking cessation therapy compared to the current standard of care, which has low success rates. This Phase I proposal will fund the initial development of the...
This Project Grant award of $320,000 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to develop a smoking and vaping cessation treatment based on the drug candidate cytisine. The goal is to explore the feasibility of delivering cytisine through electronic vape administration (EVA) to help stabilize dopamine release and reduce nicotine self-administration in a mouse model of nicotine addiction. Key activities include...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), is funding a $1,585,991 study to evaluate the efficacy of combining transcranial direct current stimulation (tDCS) with cognitive reappraisal training to reduce craving and reactivity to drug cues in individuals with cocaine use disorder. The study, being conducted at the Icahn School of Medicine at Mount Sinai, will perform a double-blind...
The National Institute on Drug Abuse (NIDA) awarded a $1,076,018 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Dynamicare Health Inc. in Wareham, MA. The award will fund a Phase II randomized clinical trial to evaluate the efficacy of DCH-003, a digital therapeutic that delivers contingency management for the treatment of stimulant use disorder. The trial will compare standard clinic care plus DCH-003 to standard care plus a sham digital app, with the...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to validate a virtual reality-based attentional bias (VR-AB) marker as a biomarker for tobacco use disorder. The $1,766,843 award will fund a study to assess the VR-AB marker's reliability, its potential as a predictive biomarker for response to the smoking cessation medication varenicline, and its viability as a candidate surrogate endpoint. The...
This Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $684,694 to New York University School of Medicine to develop and evaluate a telehealth-delivered transcranial direct current stimulation (tDCS) intervention combined with mindfulness meditation for treating cannabis use disorder (CUD). The project, titled "Telehealth-Delivered tDCS for Cannabis Addiction Recovery: The C.A.R.E.S....
The National Institute on Drug Abuse (NIDA) awarded a $306,528 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Addinex Technologies, Inc. The grant will fund the development of a medication adherence and monitoring system to support decentralized clinical trials for substance use disorder (SUD). The project aims to adapt Addinex's existing medication management system to provide researchers running SUD clinical trials with a tool for at-home dispensing that...
This Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), will fund a $2,828,440 multi-site randomized clinical trial to evaluate the efficacy of the dual GLP-1/GIP receptor agonist tirzepatide for smoking cessation and associated outcomes. The 24-week trial will be conducted by the University of Southern California and aims to expedite data on tirzepatide's potential to help treatment-seeking...
This federal Project Grant award, valued at $178,903.00, was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant funds a research study titled "Neuroimaging of Instrumental Learning Networks in Adolescent Cannabis Use Treatment" conducted by Trustees of Indiana University, doing business as Indiana University Indianapolis. The key objectives of the study are to: (1) identify associations between cannabis...